AAV re-dosing programs and the durability question
Several programs are testing whether AAV gene therapy can be re-dosed, opening the door to combinations and patients who initially failed.
AAV gene therapy has been a one-shot category by default. Several programs are now testing immune-modulation strategies that could enable re-dosing. If that works, the addressable population expands and the pricing model changes.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.